Hemochromatosis type 4 is an atypical hemochromatosis characterized by dominant inheritance, increased serum ferritin, normal transferrin saturation, and prevalent iron deposition in the reticuloendothelial (RE) cells rather than in hepatocytes. Heterozygousmissense mutations of the iron export protein ferroportin 1(FPN1)1-3 have been reported in 2 large pedigrees.4,5 We have characterized a 3–base pair deletion of FPN1 in 2 related Italians and in 1 unrelated British patient.

The Italian proband (patient 1 in Table1) was a 26-year-old female presenting with mild anemia and normal erythrocyte indices. Serum iron and transferrin saturation were slightly decreased, and serum ferritin levels, increased. Hemolytic anemia and inflammatory chronic diseases were excluded. Bone marrow aspirate showed normal erythroid maturation. Liver biopsy did not reveal fibrosis. Perl staining was positive especially in Kupffer cells, with few hepatocyte granules. Quantitative liver iron concentration (LIC) was obtained by magnetic susceptometry (SQUID).6,7 A low-intensity venesection protocol reduced ferritin without causing anemia. The proband's mother (patient 2) had breast cancer 3 years ago. She is in complete remission, having undergone radical mastectomy and chemotherapy and is being treated with tamoxifen. She has had persistent hyperferritinemia over the last 3 years. Liver function tests were normal. LIC was elevated. The British patient (patient 3) was a 30-year-old asymptomatic male whose father had been diagnosed with hemochromatosis. On presentation he had a raised ferritin but normal transferrin saturation. He had a slight degree of hepatomegaly and had normal liver function test results. On venesection this patient's ferritin concentration returned to the normal range without him becoming anemic. He has had 4.25 g iron removed.

Table 1.

Results of hematologic and clinical data of the patients studied

 Patient 1 Patient 2 Patient 3  
Age 26 58 30 
Sex M  
Hemoglobin level, g/L 115 127 146  
MCV, fL 91 96 84  
MCH level, pg 29.33 31.75 26.2  
Serum ferritin, μg/L 1022 5376 1660 
Serum iron, μg/dL 65 100 73  
Serum transferrin, mg/dL 254 204 219  
Transferrin saturation, % 18 35 24  
LIC (SQUID), μg/g tissue ww* 1083 2598 ND 
 Patient 1 Patient 2 Patient 3  
Age 26 58 30 
Sex M  
Hemoglobin level, g/L 115 127 146  
MCV, fL 91 96 84  
MCH level, pg 29.33 31.75 26.2  
Serum ferritin, μg/L 1022 5376 1660 
Serum iron, μg/dL 65 100 73  
Serum transferrin, mg/dL 254 204 219  
Transferrin saturation, % 18 35 24  
LIC (SQUID), μg/g tissue ww* 1083 2598 ND 

MCV represents mean corpuscular volume; MCH, mean cell hemoglobin; ww, wet weight; and ND, not determined.

*

Normal values are less than 400.

Mean of several determinations.

Mean of 2 determinations.

All 3 patients are heterozygotes for the His63Asp mutation inHFE. Sequencing the whole FPN1 gene of the 2 Italian patients identified a heterozygous GTT deletion, corresponding to the loss of a valine in a 3 valine repeat at position 160-162 (Val162del) of the protein, likely due to a slipped strand mispairing. The same deletion in the British patient was first detected by denaturing high performance liquid chromatography (DHPLC) and then confirmed by sequence analysis.

The finding of the same mutation in families of different ethnic origin (see accompanying articles by Devalia et al,8 page 695, and Wallace et al,9 page 692) suggests that Val162del results from multiple deletion events. Due to the mechanism of this deletion, it is likely to be the most common mutation both in hemochromatosis type 4 and possibly in non-Cys282Tyr hemochromatosis. The valine triplet where the deletion occurs is highly conserved in zebrafish, mice, and rats and is in close proximity to the Asn144His substitution,4 in the putative transmembrane domain involved in iron binding or transport. The latter finding supports the hypothesis of a “loss” rather than a “gain” of function as the pathogenic mechanism of iron accumulation in hemochromatosis type 4.10 FPN1 haploinsufficiency could represent a critical threshold for iron export of macrophages, but still be sufficient to allow iron export in enterocytes. Results on venesection indicate that, under forced conditions, iron can be mobilized from RE cells.

Supported by European Union contract QLRT-1999-02237. We thank Elanko Navaratnam for technical assistance.

References

References
1
Donovan
A
Brownlie
A
Zhou
Y
et al. 
Positional cloning of zebrafish ferroportin identifies a conserved vertebrate iron exporter.
Nature.
403
2000
776
781
2
Abboud
S
Haile
DJ
A novel mammalian iron-regulated protein involved in intracellular iron metabolism.
J Biol Chem.
26
2000
19906
19912
3
McKie
AYT
Marcian
P
Rolfs
A
et al. 
A novel duodenal iron-regulated, IREG-1, implicated in the basolateral transfer of iron to the circulation.
Molecular Cell.
5
2000
299
309
4
Njajou
OT
Vaessen
Joosse
M
et al. 
A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis.
Nature Genet.
28
2001
213
214
5
Montosi
G
Donovan
A
Totaro
A
et al. 
Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene.
J Clin Invest.
108
2001
619
623
6
Brittenham
GM
Farrell
DE
Harris
JW
et al. 
Magnetic susceptibility measurement of human iron stores.
New Engl J Med.
307
1982
1671
1675
7
Brittenham
GM
Non invasive methods for early detection of hereditary hemochromatosis.
Ann New York Acad Sci.
526
1988
199
208
8
Devalia
V
Carter
K
Walker
AP
et al. 
Autosomal dominant reticuloendothelial iron overload associated with a 3–base pair deletion in the Ferroportin 1 gene (SLC11A3).
Blood
100
2002
695
697
9
Wallace
DF
Pedersen
P
Dixon
JL
et al. 
Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis.
Blood.
100
2002
692
694
10
Fleming
RE
Sly
WS
Ferroportin mutation in autosomal dominant hemochromatosis: loss of function, gain in understanding.
J Clin Invest.
108
2001
521
522